INFLAZOME
Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.
Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors.
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.
Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”
Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors. The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”
Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome.
About Inflazome
Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome has a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes.
Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.
Inflazome is headquartered in Dublin, Ireland.
About the NLRP3 Inflammasome
Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Report by Cambridge Identifies Five Priorities to Prepare Students for a Changing World16.9.2025 08:05:00 CEST | Press release
Foster greater self-management skills to help students navigate uncertaintyReframe subject knowledge to increase its value in age of AISignpost skills more clearly so students recognise they're prepared for the futureStrengthen oracy to help students build meaningful relationshipsStrengthen the role of school as the place to build purposeful connections A major new report from the International Education group at Cambridge University Press & Assessment (Cambridge) captures the voices of nearly 7,000 teachers and students across 150 countries. It offers a unique view of how students experience education today and the skills and attributes they think are important for a future being shaped rapidly by technological advance, climate pressures, and shifting global dynamics. The report, Navigating the future: Preparing learners to thrive in a changing world, draws on responses from 3,021 teachers and 3,840 students worldwide, alongside insights from experts in education, social science, psyc
Lazard Expands Nordic Operations With the Appointment of Jesper Jensen as Managing Director and CEO of Investment Banking for Denmark16.9.2025 08:05:00 CEST | Press release
Lazard, Inc. (NYSE: LAZ) announces the expansion of Nordic operations with the appointment of Jesper Jensen as Managing Director, Financial Advisory and CEO of Denmark and the establishment of Lazard’s new office in Denmark effective September 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915634949/en/ Jesper Jensen With more than 25 years of experience and a deep connectivity in the local market, Jesper Jensen will enable Lazard to advance its presence in the country and strengthen client relationships in the Nordics. In the region, he will work closely with Gustaf Slettengren and Victor Kastensson, based in Sweden. “Jesper’s appointment reflects our determination to grow and to better address clients’ needs in the Nordic region as well as our confidence in Denmark,” stated Jean-Louis Girodolle, Co-Head of European Investment banking. “With his deeply connected Danish relationships and Lazard’s global reach, we are
Ant International’s Alipay+ to become Official Payment Partner of the Laver Cup16.9.2025 07:24:00 CEST | Press release
Laver Cup and Alipay+, part of Ant International, a leading global digital payment, digitization and financial technology provider, today formally announce a new long-term strategic partnership which will begin at Laver Cup San Francisco 2025, to be held at the Chase Center from September 19-21. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915513539/en/ The unified global wallet gateway Alipay+, along with WorldFirst and Antom – which are operated by Ant International – will become the Official Payment Partner of the Laver Cup through 2029. Ant Group's flagship service Alipay, an all-in-one digital platform for daily services in China will also join Alipay+ in the partnership. Ant International, with its associated brands Alipay+, WorldFirst and Antom, and Ant Group’s Alipay will play an important role in supporting the Laver Cup to drive fanbase growth and engagement in the Asia-Pacific region via its digital payment p
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody16.9.2025 02:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previously signed research collaboration and option agreement to discover and advance antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery engine. The antibody was generated using Biocytogen’s proprietary RenMice® platform and features high affinity, low immunogenicity, and favorable developability. Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies based on this antibody, aiming to addr
CSC Digital Brand Services Announces Integration into CrowdStrike Falcon Adversary Intelligence’s Recon to Accelerate Detection and Enforcement Against Malicious Domains15.9.2025 23:27:00 CEST | Press release
CSC, the world’s leading enterprise-class domain registrar and online brand protection provider, announced today at Fal.Con 2025 a new integration of CSC’s domain security offerings with the CrowdStrike Falcon® cybersecurity platform. The integration with Recon, a core capability within Falcon Adversary Intelligence, enables organizations to accelerate the detection and takedown of malicious domains, reducing exposure to phishing, fraud, and brand abuse. As cybercrime reaches unprecedented levels, adversaries are increasingly exploiting digital assets, brands, and domain name system (DNS) infrastructure. Traditional defenses often overlook domain portfolios, leaving organizations vulnerable to spoofing, impersonation, and account takeovers. CSC and CrowdStrike are uniting to close this gap with a comprehensive solution that integrates advanced threat intelligence, rapid detection, and global enforcement. Through this integration, clients can: Leverage the Recon capability in Falcon Adv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom